Pharsight

Invokana generic

Invokana is an anti-diabetic drug owned by Janssen Pharms. It was first authorized for market use on March 29, 2013. The active ingredient in Invokana is canagliflozin.

When will Invokana generic be available?

The generic version of Invokana is expected to be released after May 11, 2031. This is related to the expiry of its last patent, US10617668, titled 'Pharmaceutical formulations'.

Invokana uses

Invokana is used primarily for the treatment of type 2 diabetes mellitus. It is also used in reducing the risk of major adverse cardiovascular events and end-stage kidney disease in these patients. The drug can help prevent the doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure. Its efficacy is noted in both 100mg and 300mg doses per day.

Invokana patent expiration

Invokana is protected by 5 patents, the last of which will expire on May 11, 2031. These patents cover aspects like the drug compound, pharmaceutical formulations, and specific crystalline forms. The Invokana generic will likely be available post this date. Below are the details of the patent:

EPO Oppostions filed on Invokana

Invokana dosage

Want to ask something?